SEATTLE, WA, Dec. 14, 2017 (GLOBE NEWSWIRE) --
CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussing Ehave Inc.’s (OTCQB: EHVVF) rollout of its mental health data platform into the medical cannabis industry.
The cannabis industry is projected to exceed $50 billion in the U.S. and $22.6 billion in Canada over the coming years, according to Cowen & Co. and Deloitte analysts, driven by the legalization of the drug across North America. Despite the widespread legalization, many physicians remain hesitant to prescribe the drug given the lack of “gold standard” clinical data surrounding its safety and efficacy in treating medical conditions.
Ehave aims to change these dynamics by deploying its innovative mental health data platform into the medical cannabis industry. In partnership with a leading licensed producer, the company hopes to collect data to support a clinical trial of medical cannabis’ efficacy in treating post-traumatic stress disorder and other conditions.
Leading Mental Health Data Platform
Ehave has developed a mental health data platform designed for clinicians, patients, researchers, pharmaceutical companies, and payers. Through its two key components - MegaTeam and Ehave Connect - the platform is focused on leveraging the “right data” (rather than “big data”) to derive meaningful conclusions from vast data sets. This approach differentiates it from many other “big data” companies entering the space.
The MegaTeam component is a clinically validated digital assessment and rehabilitation software application designed to measure the cognitive abilities of patients with attention deficit hyperactivity disorder - or ADHD. The engaging video game-based environments include measurements like Stop Signal Reaction Time Assessment, N Back Assessment, Inhibitory Control Rehabilitation, and Working Memory Rehabilitation.
The Ehave Connect component is a cloud-based platform that enables the input, tracking, and extraction of clinical data while providing diagnosis and treatment insights to clinicians. Rather than relying on pen-and-paper assessments, the tool enables mental healthcare professionals to capture and record objective patient data through integrations with a community of third-party solutions, including licensed producers, assessments, diagnostics, and other devices.
Applications in Medical Cannabis
Ehave’s most recent focus has been in the medical cannabis industry, where its solutions are suitable for patients with PTSD, anxiety, traumatic brain injury, adult ADHD, depression, IBD, inflammation, CNS injury, and pain. Ehave Connect can be configured to capture and track the data required to evaluate cannabis-based therapeutics, from intake to assessment, treatment planning, delivery and adherence, to tracking of treatment outcomes.
On February 3, 2017, the company entered into an agreement with MedReleaf - a licensed producer under Health Canada’s ACMPR program - whereby the two companies agreed to develop a branded MedReleafApp utilizing the Ehave Connect platform to study the therapeutic use of medical cannabis. The initial focus is on the management of clinical trials to evaluate medical cannabis’ ability to relieve those suffering from PTSD. The digital intake patient platform launched in November and has experienced early success.
The long-term goal is to collect clinical data to create a data-rich network of patient information that has the potential to validate and legitimize the medical cannabis segment of the healthcare industry. Without “gold standard” assessments and clinical data, the industry has struggled to gain acceptance among mainstream doctors - even after the drug has been legalized throughout Canada and in many U.S. states.
Looking Ahead
Ehave Inc. (OTCQB: EHVVF) represents a compelling opportunity in the mental healthcare industry, particularly given its new focus on medical cannabis. Over the coming years, management plans to form strategic alliances with additional licensed producers of medical cannabis and publishers of psychological assessments, as well as cultivate relationships with pharmaceutical and insurance companies that could be instrumental in deploying its technology.
“As we ramp up our capabilities in artificial intelligence and machine learning, we begin to demonstrate the true capabilities of the Ehave platform,” said CEO Prateek Dwivedi in a recent press release. “Our platform goes beyond our best-in-class data management system to provide mental health practitioners with supplemental diagnosis data based on scoring results of multiple gold standard psychological assessments.”
Please follow the link to read the full article: http://www.cannabisfn.com/ehave-looks-validate-medical-cannabis-right-data/
For more information, visit the company’s website at www.ehave.com.
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany
Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com
Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/